专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07618968B2 Aryl triazines as LPAAT-β inhibitors and uses thereof 失效
标题翻译：芳基三嗪作为LPAAT-β抑制剂及其用途
公开(公告)号：US07618968B2
公开(公告)日：2009-11-17
申请号：US11890746
申请日：2007-08-06
申请人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A Jenkins , J Peter Klein , Anil M Kumar , John Tulinsky
发明人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A Jenkins , J Peter Klein , Anil M Kumar , John Tulinsky
IPC分类号： C07D251/20 , C07D251/22 , A61K31/53 , A61P35/00
CPC分类号： C07D403/12 , C07D251/16 , C07D251/18 , C07D251/22 , C07D405/12
摘要： The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
摘要翻译：本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

2. 发明授权

US07291616B2 Aryl triazines as LPAAT-β inhibitors and uses thereof 失效
标题翻译：芳基三嗪作为LPAAT-β抑制剂及其用途
公开(公告)号：US07291616B2
公开(公告)日：2007-11-06
申请号：US10285364
申请日：2002-10-30
申请人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A. Jenkins , J. Peter Klein , Anil M. Kumar , John Tulinsky
发明人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A. Jenkins , J. Peter Klein , Anil M. Kumar , John Tulinsky
IPC分类号： A61K31/53 , C07D251/48
CPC分类号： C07D403/12 , C07D251/16 , C07D251/18 , C07D251/22 , C07D405/12
摘要： The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
摘要翻译：本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

3. 发明授权

US07419984B2 Pyrimidines and uses thereof 失效
标题翻译：嘧啶类及其用途
公开(公告)号：US07419984B2
公开(公告)日：2008-09-02
申请号：US10671070
申请日：2003-09-24
申请人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A Jenkins , J Peter Klein , Cory T Kohm , John Tulinsky
发明人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A Jenkins , J Peter Klein , Cory T Kohm , John Tulinsky
IPC分类号： C07D239/48 , A61K31/505
CPC分类号： C07D239/48 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
摘要： The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells.
摘要翻译：本发明涉及嘧啶及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

4. 发明申请

US20080064700A1 Aryl triazines as LPAAT-beta inhibitors and uses thereof 失效
标题翻译：芳基三嗪作为LPAAT-β抑制剂及其用途
公开(公告)号：US20080064700A1
公开(公告)日：2008-03-13
申请号：US11890746
申请日：2007-08-06
申请人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott Jenkins , J. Klein , Anil Kumar , John Tulinsky
发明人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott Jenkins , J. Klein , Anil Kumar , John Tulinsky
IPC分类号： A61K31/53 , A61P35/00 , C07D251/42 , C07D251/48 , C07D403/10 , C07D407/02 , C12N5/00
CPC分类号： C07D403/12 , C07D251/16 , C07D251/18 , C07D251/22 , C07D405/12
摘要： The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
摘要翻译：本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

5. 发明授权

US06878715B1 Therapeutic compounds for inhibiting interleukin-12 signals and method for using same 失效
标题翻译：用于抑制白细胞介素-12信号的治疗化合物及其使用方法
公开(公告)号：US06878715B1
公开(公告)日：2005-04-12
申请号：US09544984
申请日：2000-04-07
申请人： J. Peter Klein , Stephen J. Klaus , Anil M. Kumar , Baoqing Gong
发明人： J. Peter Klein , Stephen J. Klaus , Anil M. Kumar , Baoqing Gong
IPC分类号： A61K31/00 , C07D239/54 , C07D473/04 , C07D473/06 , C07D473/10 , C07D487/04 , C07D495/04 , C07D513/04 , A61K31/522
CPC分类号： C07D239/54 , A61K31/00 , C07D473/04 , C07D473/06 , C07D473/10 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S. Each R1, R2 and R3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：发现具有与五元环结构稠合的六元环结构的新型杂环化合物可用于治疗和预防与受白细胞介素-12（“IL-12”）影响的紊乱相关的症状或表现，，例如，Th1细胞介导的疾病。治疗化合物，药学上可接受的衍生物（例如分解的对映异构体，非对映异构体，互变异构体，其盐和溶剂合物）或其前药具有以下通式：每个X，Y和Z独立地选自C （R 3），N，N（R 3）和S.每个R 1，R 2和R 3是取代或未取代的，并且独立地选自氢，卤素，氧代，C（1-20）烷基，C （1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1 （1-20）氨基烷基，C（1-20）四氨基烷基，C（5-15）氨基三烷氧基氨基，C（1-20）烷基酰氨基，C（1-20）烷基氨基烷基，C（1-20））烷基酰氨基烷基，C（1-20）酰氨基烷基，C（1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基，和C（1-20）二烷氧基烷基。

6. 发明授权

US06774130B2 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same 失效
标题翻译：用于抑制白细胞介素-12信号的治疗化合物及其使用方法
公开(公告)号：US06774130B2
公开(公告)日：2004-08-10
申请号：US09288556
申请日：1999-04-09
申请人： J. Peter Klein , Stephen J. Klaus , Anil M. Kumar , Baoqing Gong
发明人： J. Peter Klein , Stephen J. Klaus , Anil M. Kumar , Baoqing Gong
IPC分类号： A61K31522
CPC分类号： C07D473/04 , A61K31/00 , C07D473/06 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S. Each R1, R2 and R3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：发现具有与五元环结构稠合的六元环结构的新型杂环化合物可用于治疗和预防与受白细胞介素-12（“IL-12”）影响的紊乱相关的症状或表现，，例如，Th1细胞介导的疾病。治疗化合物，药学上可接受的衍生物（例如分解的对映异构体，非对映异构体，互变异构体，其盐和溶剂合物）或其前药具有以下通式：每个X，Y和Z独立地选自C （R 3），N，N（R 3）和S.每个R 1，R 2和R 3是取代或未取代的，并且独立地选自氢，卤素，氧代，C（1-20）烷基，C （1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1 （1-20）氨基烷基，C（1-20）四氨基烷基，C（5-15）氨基三烷氧基氨基，C（1-20）烷基酰氨基，C（1-20）烷基氨基烷基，C（1-20））烷基酰氨基烷基，C（1-20）酰氨基烷基，C（1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基，和C（1-20）二烷氧基烷基。

7. 发明申请

US20100189726A1 LPAAT-BETA INHIBITORS AND USES THEREOF 审中-公开
标题翻译： LPAAT-BETA抑制剂及其用途
公开(公告)号：US20100189726A1
公开(公告)日：2010-07-29
申请号：US12569639
申请日：2009-09-29
申请人： Lynn BONHAM , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung , Baoqing Gong , John Tulinsky
发明人： Lynn BONHAM , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung , Baoqing Gong , John Tulinsky
IPC分类号： A61K31/53 , C07D251/50 , C07D405/12 , C07D251/52 , A61K39/00 , A61P35/00
CPC分类号： C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
摘要： The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.
摘要翻译：本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶的用途。（LPAAT-＆bgr）活动。本发明还涉及使用所述三嗪治疗癌症的方法。本发明还涉及用于筛选LPAAT-＆bgr的方法; 活动。

8. 发明授权

US07608620B2 LPAAT-β inhibitors and uses thereof 失效
标题翻译： LPAAT-β抑制剂及其用途
公开(公告)号：US07608620B2
公开(公告)日：2009-10-27
申请号：US11601513
申请日：2006-11-16
申请人： Lynn Bonham , Baoqing Gong , Robert E Finney , David M Hollenback , J Peter Klein , David W Leung , Scott A Shaffer , Norina M Tang , John Tulinsky , Thayer H White
发明人： Lynn Bonham , Baoqing Gong , Robert E Finney , David M Hollenback , J Peter Klein , David W Leung , Scott A Shaffer , Norina M Tang , John Tulinsky , Thayer H White
IPC分类号： C07D251/52 , C07D251/38 , A61K31/53 , A61P35/00
CPC分类号： C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
摘要： The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.
摘要翻译：本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。本发明还涉及使用所述三嗪治疗癌症的方法。本发明还涉及用于筛选LPAAT-β活性的方法。

9. 发明授权

US07064125B2 LPAAT-β inhibitors and uses thereof 失效
公开(公告)号：US07064125B2
公开(公告)日：2006-06-20
申请号：US10712900
申请日：2003-11-13
申请人： Baoqing Gong , John Tulinsky , Lynn Bonham , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung
发明人： Baoqing Gong , John Tulinsky , Lynn Bonham , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung
IPC分类号： A01N43/66
CPC分类号： C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
摘要： The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.

10. 发明授权

US07199238B2 LPAAT-β inhibitors and uses thereof 失效
公开(公告)号：US07199238B2
公开(公告)日：2007-04-03
申请号：US11224340
申请日：2005-09-12
申请人： Lynn Bonham , Baoqing Gong , Robert E Finney , David M Hollenback , J. Peter Klein , David W Leung , Scott A Shaffer , Norina M Tang , John Tulinsky , Thayer H White
发明人： Lynn Bonham , Baoqing Gong , Robert E Finney , David M Hollenback , J. Peter Klein , David W Leung , Scott A Shaffer , Norina M Tang , John Tulinsky , Thayer H White
IPC分类号： C07D251/52 , C07D251/38 , A61K31/53 , A61P35/00
CPC分类号： C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
摘要： The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式